Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany

Augustin, Matthias; Wirth, Daniel; Mahlich, Jörg; Pepper, Alicia N.; Druchok, C.

doi:10.1080/09546634.2020.1793891

Cited by 12 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment costs were calculated for each patient in the model based on the combination of therapies they received, the treatment duration for each product in the sequence, and the cost of therapies. Costs associated with administration, monitoring and adverse events were not considered in the model as they comprise less than 2% of the overall costs [12].…”

Section: Drug Costsmentioning

confidence: 99%

Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain

Egeberg

Danø²,

Pedersen³

et al. 2021

Journal of Medical Economics

View full text Add to dashboard Cite

The purpose of this manuscript was to illustrate the impact of the place in the treatment sequence on the cost and cost-effectiveness of different biologics for patients with moderate-to-severe plaque psoriasis. Materials and MethodsWe developed a treatment sequence model and focused on seven different biological treatment options and 840 combinations of treatment sequences. The model converted cost of treatment to a cost per responder by dividing treatment cost by expected number of patients achieving PASI100 after 52 weeks of treatment. We used Spanish ex-factory price levels, dosing recommendations and real-world data on drug survival to calculate the treatment costs. ResultsThe most cost-effective treatment sequence was brodalumab-risankizumab-guselkumabixekizumab, with a cost per responder of €139,281 during the first five years of treatment. In comparison, if brodalumab was not recommended as first-line therapy, total costs would increase by 7.4% to €149,616. If brodalumab was not recommended as any of the first four lines of treatment, total costs would increase by 13.1% to €157,527 relative to the most cost-effective treatment sequence. Conclusions.A sequential therapy model may improve efficiency in the treatment of psoriasis. According to our A c c e p t e d M a n u s c r i p t results, brodalumab as the first-line therapy in Spain leads to the most cost-effective treatment sequence.

show abstract

Section: Drug Costsmentioning

confidence: 99%

Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain

Egeberg

Danø²,

Pedersen³

et al. 2021

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

“…These findings are consistent with other cost-effectiveness analyses conducted in the United States, Japan, Germany, Portugal, and Saudi Arabia. 19,[24][25][26][27] In the next 4 years, the number of scripts dispensed for the use of secukinumab alone to treat chronic plaque psoriasis is expected to more than double, costing the Australian health care system in excess of AUD90 million. 28 Given that tildrakizumab produces cost savings of AUD4,416 per year, per patient, when compared with secukinumab, the cost savings of adopting tildrakizumab as a first-line treatment could be significant.…”

Section: Discussionmentioning

confidence: 99%

“…These findings are consistent with other cost-effectiveness analyses conducted in the United States, Japan, Germany, Portugal, and Saudi Arabia. 19 , 24 , 25 , 26 , 27 …”

Section: Discussionmentioning

confidence: 99%

Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis

et al. 2021

View full text Add to dashboard Cite

Background: Biologics are a good therapeutic option for severe, chronic plaque psoriasis; however, they come with significant cost to the health care system.Objective: To conduct a cost-utility analysis of outpatient biologics (adalimumab, etanercept, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab, and ustekinumab) available to adults with severe, chronic plaque psoriasis from the perspective of the Australian health care system.Methods: A Markov cohort model was constructed to estimate the quality-adjusted life years (QALYs) and costs accrued for treatment pathways commencing with different first-line biologics, over a 96-week time horizon. The model adhered to the Australian Pharmaceutical Benefits Scheme eligibility criteria and guidelines.Results: A biologic treatment pathway commencing on tildrakizumab was the most cost-effective first-line treatment (Australian dollar 39,930; total utility of 1.57 QALYs over 96 weeks). First-line secukinumab and risankizumab had incremental cost-utility ratios of Australian dollar 194,524/QALY and Australian dollar 479,834/QALY, respectively, when compared with first-line tildrakizumab. Limitations:The efficacy and utility input parameters were derived from international randomized control trials and patients from the United Kingdom, respectively. Findings from this study cannot be generalized beyond Australia. Conclusion:Tildrakizumab may be considered as first-line treatment for adult patients with severe, chronic plaque psoriasis embarking on biologic therapy, from the economic perspective of the Australian health care system.

show abstract

“… 25 Further, more advanced biologicals have been shown to be more cost-effective than first-generation drugs. 26 27 Monoclonal antibodies, selective for the interleukin (IL)-23p19 subunit inhibition, represent a new standard of treatment currently available for the long-term management of psoriasis. 28 Among these, tildrakizumab has demonstrated long-term efficacy and safety in the pivotal phase III studies (reSURFACE 1 and 2) comparing tildrakizumab versus placebo or etanercept for moderate-to-severe psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)

et al. 2023

Self Cite

View full text Add to dashboard Cite

IntroductionPsoriasis is a chronic inflammatory skin disease that negatively impacts the quality of life of patients and their families. However, the most commonly used decision-making tools in psoriasis, Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA) and Dermatology Life Quality Index (DLQI), do not fully capture the impact of psoriasis on patients’ lives. In contrast, the well-established 5-item WHO Well-being Index (WHO-5) assesses the subjective psychological well-being of patients. Moreover, while drug innovations became available for psoriasis, data on the impact of these therapies on patients’ lives and their closest environment (family, physicians) are limited. This study will assess the effect of tildrakizumab, an interleukin-23p19 inhibitor, on the overall well-being of patients with moderate-to-severe psoriasis. Moreover, the long-term benefit of tildrakizumab on physicians' satisfaction and partners' lives of patients with psoriasis will be evaluated.Methods and analysisThis non-interventional, prospective, observational, real-world evidence study will involve multiple sites in Europe and approximately 500 adults with moderate-to-severe psoriasis treated with tildrakizumab. Each patient will be followed for 24 months. The primary endpoint is well-being measured by the WHO-5 questionnaire. Key secondary endpoints include Physician’s Satisfaction and partner’s quality of life (FamilyPso). Other endpoints will evaluate skin-generic quality of life (DLQI-R), Treatment Satisfaction Questionnaire for Medication (TSQM-9), Treatment-related Patient Benefit Index ‘Standard’, 10 items (PBI-S-10) and work productivity and activity impairment due to psoriasis (WPAI:PSO). Statistical analyses will be based on observed cases. Multiple imputations will be performed as a sensitivity analysis, and adverse events will be reported.Ethics and disseminationThe study will be conducted according to the protocol, which received ethics committee approval and applicable regulatory requirements of each participating country. The results will be disseminated through scientific publications and congress presentations.Trail registration numberClinicalTrials.gov Identifier:NCT04823247(Pre-results)

show abstract

Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany

Cited by 12 publications

References 37 publications

Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain

Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain

Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis

Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)

Contact Info

Product

Resources

About